The Food and Drug Administration approved Cytori Therapeutics Inc.'s (Nasdaq: CYTX) Investigational Device Exemption for a pilot clinical trial to evaluate Cytori Cell Therapy in patients with thermal burn injury. The stock price climbed 35 cents to close at $1.72.
FDA approves Cytori Therapeutics' exemption
April 10, 2017 at 17:16 PM EDT
